WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) between February 5, 2021 and May 14, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 3, 2024. WHAT TO DO NEXT: To join the Bolt class action, go to https://rosenlegal.com/submit-form/?case_i ...

Historically, Bolt's lead asset was BDC-1001, which had pre-defined success criteria that included an overall response rate efficacy threshold of at least 30% and, according to Bolt, purportedly "provide[d] a compelling example of the potential of Boltbody ISACs to address unmet medical needs in solid tumors" by "targeting HER2-expressing tumors and related metastatic disease, triggering their destruction by the innate and adaptive immune systems." Pomerantz LLP, with offices in New York, Chicago, Los Angel ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 24, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ: BOLT) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Bolt investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorn ...

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ: BOLT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Bolt and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 14, 20 ...

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Willie Quinn - Incoming Chief Executive Officer Randy Schatzman - Outgoing Chief Executive Officer Edith Perez - Outgoing Chief Medical Officer Michael Alonso - Co-Founder of Bolt and Senior Vice President of Research Dawn Colburn - Senior Vice President of Clinical Development. Conference Call Participants Jeffrey La Rosa - Leerink Partners Stephen Willey - Stifel Michael Schmidt - Guggenh ...

NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ: BOLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. Attorney advertising. Prior results do not guarantee similar outcomes. The investigation concerns whether Bolt and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. CONTACT: D ...

| --- | --- | |--------------------------|-------------------------------------------------------------------------------------------------------| | | | | | BOLT BIOTHERAPEUTICS, INC. | | Date: May 14, 2024 | By: /s/ Randall C. Schatzman, Ph.D. | | | Randall C. Schatzman, Ph.D. Chief Executive Officer (Principal Executive Of icer) | | | | | Date: May 14, 2024 | By: /s/ William P. Quinn | | | William P. Quinn Chief Financial Officer (Principal Financial and Accounting Of icer) | 30 None. 27 Item 4. Mine Safe ...

Table of Contents Some of these events could be the basis for FDA action, including injunction, recall, seizure or total or partial suspension of production. In addition, our third-party manufacturers and suppliers are subject to FDA inspection from time to time. Failure by our third-party manufacturers and suppliers to pass such inspections and otherwise satisfactorily complete the FDA approval regimen with respect to our product candidate may result in regulatory actions such as the issuance of FDA Form 4 ...

Exhibit 99.1 Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update – BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones – BDC-3042 Phase 1 study successfully cleared safety assessments in the first three dose level cohorts – Cash balance of $128.6 million as of December 31, 2023, anticipated to fund key milestones through late 2025 "We made substantial progress advancing our two proprie ...

Item 1A. Risk Factors. None. 31 None. X X X X SIGNATURES The following table sets forth a summary of our cash flows for each of the periods indicated: License Agreements with Stanford University FORM 10-Q | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------|-----------------------------------------|-------|-----------|--------|-------------------------------------------------------|------------------|---------|----------- ...